A MULTICENTER, OPEN-LABEL, PHASE 1B STUDY TO ASSESS THE PHARMACOKINETICS, SAFETY, AND TOLERABILITY OF SULBACTAM-DURLOBACTAM IN HOSPITALIZED PEDIATRIC PATIENTS FROM BIRTH TO <18 YEARS WHO ARE RECEIVING SYSTEMIC ANTIBIOTIC THERAPY FOR SUSPECTED OR CONFIRM

Project: Research project

Project Details

StatusActive
Effective start/end date12/23/24 → 12/22/29

Funding

  • Entasis Therapeutics ( Award # ): $17,000.00